Arcutis Biotherapeutics, Inc. (ARQT) Earnings Call Transcripts

Arcutis Biotherapeutics, Inc.'s Latest Earnings Call - June 9, 2026

In Q2 2026, Arcutis Biotherapeutics reported strong growth driven by its flagship product, ZORYVE. The company achieved cash flow positivity, allowing further investment in R&D. Revenue grew 65% YoY, although it declined 17% QoQ due to seasonal effects and severe weather. Management reiterated peak sales guidance for ZORYVE at $2.5 billion to $3 billion. Upcoming catalysts include FDA approval for ZORYVE in younger age groups and ongoing trials for new indications.

Reported metrics

Guidance from management

Management maintained guidance for ZORYVE's peak sales at $2.5 billion to $3 billion and expects FDA approval for new indications by June 29, 2026.

What management said

No, I was going to add something similar. So yes, I think also some of that effect -- you would have seen it prolong in March when we didn't -- we saw the demand pick up. So I don't think there's anything that signals that there's an undue co-pay burn in Q2, and we've seen strong volume growth in the last quarter to date of Q2 to date versus last Q1. So that's also another signal that we don't think there's any impac...

The change between [indiscernible] really only affects the patient's co-pay. I think it's highly unlikely that they would produce in a preferred position. Being a branded on the formulary period is a big deal. There are no other branded topicals on the Medicare formularies. So we were very happy to get nonpreferred quite frankly. And I think for us to rebate our way down to being preferred, we probably have to get do...

What analysts pressed on

Analysts expressed concerns about the impact of macroeconomic factors like inflation on sales and the potential for increased competition in the dermatology space. Questions were raised about the scalability of the sales force and the timeline for Medicare coverage expansion.

Main topics on the call

• ZORYVE Growth and Peak Sales Potential — Management reiterated that ZORYVE is expected to generate $2.5 billion to $3 billion in peak sales. The product is in early growth stages, and management is confident in its market potential.
• Cash Flow Positive Status — Arcutis has achieved cash flow positivity, enabling reinvestment in ZORYVE's growth and new R&D initiatives. This positions the company as a self-sustaining biotech firm.
• Upcoming FDA Approvals and Trials — The company expects FDA approval for ZORYVE in psoriasis for 2- to 5-year-olds by June 29, 2026, and has filed for approval in atopic dermatitis for 3 to 24 months old. Phase II trials for vitiligo and HS are ongoing.
• Impact of Inflation and Macroeconomic Factors — Management does not expect significant impact from inflation due to fixed co-pays for commercial and Medicaid patients. Medicare is not a major revenue source yet.

Read the full Arcutis Biotherapeutics, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 33 Arcutis Biotherapeutics, Inc. earnings call transcripts on record, spanning September 15, 2021 to August 5, 2026. Based on this history, Arcutis Biotherapeutics, Inc. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ARQT

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

33

First call

September 15, 2021

Most recent

August 5, 2026

Reporting cadence

quarterly